
BIO MEDICA LABORATORIES L (BMLL-SM) Share Price Rises 11.56% Today
Updated: 29 Jul 2026 • 12:02 pm
Posted by:

Bio Medica Laboratories L Share Price rises 11.56% to Rs 157.35, with a market cap of Rs 177.37 crore.
Bio Medica Laboratories L Share Price has experienced a significant rise today, closing at Rs 157.35, marking an 11.56% increase from its previous close of Rs 141.05. This price movement has propelled the company's market capitalisation to Rs 177.37 crore, categorising it as a Micro Cap stock. The substantial gain positions Bio Medica Laboratories L as a top gainer in the market today. Despite the absence of a specific catalyst in the supplied data, the price rise is noteworthy and warrants a closer examination of the stock's technical and fundamental aspects.
BIO MEDICA LABORATORIES L (BMLL-SM) Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 157.35 |
| Previous Close | Rs 141.05 |
| Today's Change | +Rs 16.3 (+11.56%) |
| Day Open | Rs 140 |
| Day High | Rs 161.7 |
| Day Low | Rs 140 |
| Current Volume (NSE) | 1,16,000 |
| NSE Traded Volume | 1,16,000 |
| Combined NSE + BSE Volume | 1,16,000 |
| Turnover | Rs 1.83 crore |
| Market Capitalisation | Rs 177.37 crore |
| Market Cap Category | Micro Cap |
BIO MEDICA LABORATORIES L (BMLL-SM) traded at Rs 157.35. versus the previous close of Rs 141.05, a rise of 11.56%. The stock opened at Rs 140, reached Rs 161.7, touched Rs 140. Reported volume was 1,16,000.
BIO MEDICA LABORATORIES L (BMLL-SM) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 177.37 crore |
| P/E Ratio | 15.2x |
| P/B Ratio | 9.78x |
| ROE | 13.67% |
| ROCE | 10.17% |
| EPS | Rs 9.28 |
| Dividend Yield | 0% |
BIO MEDICA LABORATORIES L was valued at a P/E ratio of 15.2x, a P/B ratio of 9.78x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.
Profitability and capital efficiency were represented by ROE of 13.67% and ROCE of 10.17%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.
Per-share and shareholder-return metrics included EPS of Rs 9.28, dividend yield of 0%. Dividend yield is a current or historical ratio and does not guarantee future distributions.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 15.2x |
| Benchmark Median P/E | 26.37x |
| Benchmark Average P/E | 80.74x |
| Benchmark P/E Range | 3.61x to 3,439.3x |
| Company P/B Ratio | 9.78x |
| Benchmark Median P/B | 1.82x |
| Company ROE | 13.67% |
| Benchmark Median ROE | 10.31% |
| Company ROCE | 10.17% |
| Benchmark Median ROCE | 12.96% |
| Company Market Capitalisation | Rs 177.37 crore |
| Benchmark Median Market Cap | Rs 147.71 crore |
BIO MEDICA LABORATORIES L (BMLL-SM) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs. The numerical benchmark uses 137 same industry companies from the supplied master-data set.
BIO MEDICA LABORATORIES L (BMLL-SM) has a P/E ratio of 15.2x, which is below the benchmark median of 26.37x, a difference of -42.36%. The benchmark contains 103 companies with P/E data, ranging from 3.61x to 3,439.3x. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
BIO MEDICA LABORATORIES L (BMLL-SM) has a ROE of 13.67%, which is above the benchmark median of 10.31%, a difference of +32.59%. BIO MEDICA LABORATORIES L (BMLL-SM) has a ROCE of 10.17%, which is below the benchmark median of 12.96%, a difference of -21.53%.
Track today's top gainers through the Univest top gainers screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Dishman Carbogen Amcis Ltd. | DCAL | 2,921.65 | 29.31 | 0.43 | -2.89 | -0.26 |
| Kwality Pharmaceuticals Ltd. | KPL | 2,815.27 | 39.89 | 8.12 | 28.21 | 26.35 |
| Hikal Ltd. | HIKAL | 2,738.51 | 0 | 2.23 | 15.22 | 16.15 |
| Panacea Biotec Ltd. | PANACEABIO | 2,653.99 | 0 | 3.04 | 0 | 5.36 |
| Sai Parenteral's Ltd. | SAIPARENT | 2,476.69 | 169.37 | 3.13 | 13.9 | 12.97 |
BIO MEDICA LABORATORIES L (BMLL-SM) has a P/E ratio of 15.2x compared with the displayed peer median of 29.31x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 13.67% compares with a peer median of 13.9% across the companies shown in the table. ROCE stood at 10.17% versus the displayed peer median of 12.97%, providing a capital-efficiency comparison. BIO MEDICA LABORATORIES L (BMLL-SM) has a market capitalisation of Rs 177.37 crore. Among the 5 peers shown, 5 have a larger market capitalisation.
Why Investors Are Watching Bio Medica Laboratories L
Investors are closely monitoring Bio Medica Laboratories L due to its recent price action and sector positioning.
- Price Action: Today's 11.56% rise positions it as a top gainer.
- Fundamentals: Competitive P/E ratio and strong ROE.
- Sector: Operates in the dynamic Pharmaceuticals & Drugs industry.
- Valuation: Premium P/B ratio compared to peers.
As the company continues to navigate the competitive landscape of the Pharmaceuticals & Drugs industry, investors should keep an eye on its operational efficiency and market positioning.
About Bio Medica Laboratories L
Bio Medica Laboratories L is a key player in the Healthcare sector, specifically within the Pharmaceuticals & Drugs industry. The company focuses on developing and manufacturing pharmaceutical products, catering to a diverse range of medical needs. Its operations are aligned with industry standards, ensuring quality and efficacy in its product offerings. As a Micro Cap company, Bio Medica Laboratories L leverages its niche expertise to maintain a competitive edge in the market. The company's strategic initiatives and product innovations are designed to address the evolving demands of the healthcare sector, positioning it for sustainable growth and market relevance.
Track Bio Medica Laboratories L Share Price on Univest
Use BIO MEDICA LABORATORIES L (BMLL-SM) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top gainers lists and related market analysis.
Investors and market enthusiasts can track Bio Medica Laboratories L Share Price on Univest for real-time updates. Univest provides comprehensive insights into the company's technical indicators, fundamental ratios, shareholding patterns, and market trends. Stay informed about the latest developments and make data-driven decisions by leveraging Univest's robust analytical tools and resources.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What is the current share price of Bio Medica Laboratories L?
Ans. The current share price of Bio Medica Laboratories L is Rs 157.35, reflecting an 11.56% increase from the previous close of Rs 141.05. The stock moved 11.56% during the session.
Why did Bio Medica Laboratories L share price rise today?
Ans. The share price of Bio Medica Laboratories L rose by 11.56% today, but the supplied data does not specify a company-specific catalyst for this increase. The stock moved 11.56% during the session.
What is the market capitalisation of Bio Medica Laboratories L?
Ans. Bio Medica Laboratories L has a market capitalisation of Rs 177.37 crore, categorising it as a Micro Cap stock in the Pharmaceuticals & Drugs industry. The company operates in the Healthcare sector.
How does Bio Medica Laboratories L's P/E ratio compare to the industry?
Ans. Bio Medica Laboratories L's P/E ratio of 15.2 is below the industry median of 26.37, indicating a potentially undervalued position relative to its peers. The company trades at a P/E ratio of 15.2x.
What is the ROE of Bio Medica Laboratories L?
Ans. The ROE of Bio Medica Laboratories L is 13.67%, which is above the industry median of 10.31%, showcasing efficient use of shareholder equity. ROE stands at 13.67%. ROCE stands at 10.17%.
What is the P/B ratio of Bio Medica Laboratories L?
Ans. The P/B ratio of Bio Medica Laboratories L is 9.78, significantly higher than the industry median of 1.82, indicating a premium valuation. The company trades at a P/E ratio of 15.2x.
How does Bio Medica Laboratories L's ROCE compare to peers?
Ans. Bio Medica Laboratories L's ROCE of 10.17% is lower than peers like Beta Drugs Ltd. (22.17%) and Kwality Pharmaceuticals Ltd. (26.35%), indicating potential areas for improvement. ROE stands at 13.67%.
What industry does Bio Medica Laboratories L operate in?
Ans. Bio Medica Laboratories L operates in the Pharmaceuticals & Drugs industry, part of the broader Healthcare sector, focusing on pharmaceutical product development and manufacturing. The stock belongs to the Healthcare sector.
Where can I track Bio Medica Laboratories L share price?
Ans. You can track Bio Medica Laboratories L share price on Univest, which provides real-time updates, technical indicators, and fundamental analysis. The stock moved 11.56% during the session. The intraday range extended from Rs 140 to Rs 161.7.
Recent Articles

SBI Long Term Advantage Fund - Series VI vs Sundaram Series III Direct IDCW Payout: NAV, Returns and Maturity Status Compared
29 July 2026

SBI Long Term Advantage Fund - Series VI vs ICICI Prudential Wealth Enhancement Fund: NAV, Returns and Maturity Status Compared
29 July 2026

Sundaram Long Term Tax Advantage Fund Series I vs Bank of India Mid Cap Tax Fund Series 1 Direct IDCW: NAV, Returns and Maturity Status Compared
29 July 2026

UTI Long Term Advantage Fund Series IV vs Bank of India Mid Cap Tax Fund Series 1 Direct IDCW: NAV, Returns and Maturity Status Compared
29 July 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
SBI Long Term Advantage Fund - Series VI vs Sundaram Series III Direct IDCW Payout: NAV, Returns and Maturity Status Compared
SBI Long Term Advantage Fund - Series VI vs ICICI Prudential Wealth Enhancement Fund: NAV, Returns and Maturity Status Compared
Sundaram Long Term Tax Advantage Fund Series I vs Bank of India Mid Cap Tax Fund Series 1 Direct IDCW: NAV, Returns and Maturity Status Compared
UTI Long Term Advantage Fund Series IV vs Bank of India Mid Cap Tax Fund Series 1 Direct IDCW: NAV, Returns and Maturity Status Compared
SBI Long Term Advantage Fund - Series VI vs Sundaram Series III Regular: NAV, Returns and Maturity Status Compared
Popular this week
SBI Long Term Advantage Fund - Series VI vs Sundaram Series III Direct IDCW Payout: NAV, Returns and Maturity Status Compared
SBI Long Term Advantage Fund - Series VI vs ICICI Prudential Wealth Enhancement Fund: NAV, Returns and Maturity Status Compared
Sundaram Long Term Tax Advantage Fund Series I vs Bank of India Mid Cap Tax Fund Series 1 Direct IDCW: NAV, Returns and Maturity Status Compared
UTI Long Term Advantage Fund Series IV vs Bank of India Mid Cap Tax Fund Series 1 Direct IDCW: NAV, Returns and Maturity Status Compared
SBI Long Term Advantage Fund - Series VI vs Sundaram Series III Regular: NAV, Returns and Maturity Status Compared

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





